Recent insight into the role of FBXW7 as a tumor suppressor

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• FBXW7 (F-box and WD repeat domain-containing 7) is a key tumor suppressor and the most frequently mutated F-box protein in human cancers.
• It acts as the substrate recognition module for SCF E3 ubiquitin ligase complexes, targeting numerous oncoproteins for degradation.
• Dysregulation of FBXW7 contributes significantly to cancer development by stabilizing oncoproteins.

Purpose of the Study:

• To provide a comprehensive review of the molecular and biological characteristics of FBXW7 and its substrates.
• To elucidate the impact of FBXW7 mutations on the initiation and progression of various cancers.
• To explore the therapeutic potential of targeting FBXW7 in anticancer strategies.

Main Methods:

• Literature review of molecular and biological studies on FBXW7.
• Analysis of mutation data and their correlation with cancer development.
• Review of preclinical and clinical research on FBXW7-targeting therapies.

Main Results:

• FBXW7 regulates the degradation of critical oncoproteins including c-MYC, NOTCH, KLF5, cyclin E, c-JUN, and MCL1.
• Mutations in FBXW7 disrupt its tumor-suppressive function, leading to oncoprotein accumulation and promoting tumorigenesis.
• Evidence suggests FBXW7 status can predict patient response to certain therapies.

Conclusions:

• FBXW7 is a pivotal regulator of cellular homeostasis and a critical tumor suppressor.
• Understanding FBXW7 mutations and their functional consequences is essential for cancer research.
• Targeting FBXW7 presents a promising avenue for novel anticancer therapies.